How do you decide for which high-risk post-menopausal women to extend adjuvant endocrine therapy after completing 5 years?

And how long? According to the ABCSG-16 Trial there was no difference in extending AI beyond 2 years after an initial 5 years.

Answer from: Medical Oncologist at Academic Institution

Ever since the MA.17R data was presented by Paul Goss at the ASCO plenary session in 2016 and its simultaneous publication in NEJM, extended aromatase inhibitor therapy has been a topic of great interest. This study did show an nearly 4% absolute benefit for the longer duration as far as DFS was con...

Comments

Medical Oncologist at St Jude Heritage Medical Group
How about 7 yrs instead of 10

Answer from: Medical Oncologist at Academic Institution

The recent EBCTCG meta analysis suggested a bigger benefit as the nodal burden increased (especially N2). Also more in breast recurrences than distant events were prevented so women who do breast conservation may benefit more. The CTS5 online calculator or a genomic test such as the BCI assay can al...

Please select the option that best describes you:

How do you decide for which high-risk post-menopausal women to extend adjuvant endocrine therapy after completing 5 years?

Related Questions